- Home
- APVO vs KWE Comparison
APVO vs KWE Comparison
Compare APVO & KWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- KWE
- Stock Information
- Founded
- APVO 2016
- KWE 2017
- Country
- APVO United States
- KWE Canada
- Employees
- APVO N/A
- KWE N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- KWE
- Sector
- APVO Health Care
- KWE
- Exchange
- APVO Nasdaq
- KWE Nasdaq
- Market Cap
- APVO 3.3M
- KWE 3.2M
- IPO Year
- APVO N/A
- KWE N/A
- Fundamental
- Price
- APVO $0.67
- KWE $5.14
- Analyst Decision
- APVO Strong Buy
- KWE
- Analyst Count
- APVO 1
- KWE 0
- Target Price
- APVO $296.00
- KWE N/A
- AVG Volume (30 Days)
- APVO 8.7M
- KWE 423.8K
- Earning Date
- APVO 05-07-2025
- KWE 05-15-2025
- Dividend Yield
- APVO N/A
- KWE N/A
- EPS Growth
- APVO N/A
- KWE N/A
- EPS
- APVO N/A
- KWE N/A
- Revenue
- APVO N/A
- KWE $1,572,738.00
- Revenue This Year
- APVO N/A
- KWE N/A
- Revenue Next Year
- APVO N/A
- KWE N/A
- P/E Ratio
- APVO N/A
- KWE N/A
- Revenue Growth
- APVO N/A
- KWE 116.30
- 52 Week Low
- APVO $0.60
- KWE $0.22
- 52 Week High
- APVO $51.06
- KWE $243.60
- Technical
- Relative Strength Index (RSI)
- APVO 30.74
- KWE 49.11
- Support Level
- APVO $0.60
- KWE $0.22
- Resistance Level
- APVO $0.80
- KWE $7.20
- Average True Range (ATR)
- APVO 0.19
- KWE 0.64
- MACD
- APVO 0.03
- KWE 0.17
- Stochastic Oscillator
- APVO 6.97
- KWE 70.50
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About KWE KWESST Micro Systems Inc.
KWESST Micro Systems Inc develops and commercializes next-generation tactical systems. The company offers breakthrough technology in lethal and non-lethal systems with broad application, including law enforcement and personal defence, modernized digitization of tactical forces for shared situational awareness and targeting, and counter-measures against threats such as drones, lasers and electronic detection.